PLL Therapeutics focuses on restoring gut permeability. Its initial indication is Amyotrophic Lateral Sclerosis (ALS), a fatal motor neuron disease. The company’s therapy, PLL001, consists of several ...

Positive results of preclinical studies confirm the potential of Neurizon’s lead drug candidate NUZ-001 to be a ...

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...

The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

The St. Peter’s Hospital ALS Regional Center gives specialized services and resources to people with Amyotrophic Lateral ...

Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon's lead drug NUZ-001 and its major active metabolite significantly and ...

Lee Wilson discovered she has a "100%" chance of developing ALS, after losing her father and grandmother to the disease ...

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, ultimately leading to muscle weakness and paralysis. ALS is an orphan disease, but its ...

A new AI-powered interpreter is expected to simulate speakers’ voices in different languages during Microsoft Teams meetings.

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to ...

Fintel reports that on November 18, 2024, Baird upgraded their outlook for Amylyx Pharmaceuticals (NasdaqGS:AMLX) from ...

For example, while we know that getting a good workout in can benefit the nervous system by boosting our mood and helping us ...